NOTRELOAD AI
  • NOTRELOAD AI
  • Invest ↗
  • myNOTRELOAD (BETA)
  • XY Feed
  • 24-HOUR Pass →
Sign in Subscribe

MAIA Biotech CEO & Directors Buy 182K Shares

MAIA Biotechnology's CEO and board members purchased 182,445 shares in late November 2025, signaling strong confidence in their cancer drug development program.

MAIA Biotech CEO & Directors Buy 182K Shares
Already have an account? Sign in.
12/01/2025 · 11:34 AM
MAIA
/ Read more

Feed↓

Raymond James Highlights Viking’s New Amylin-Based Weight Loss Drug VK3019 Entering Clinic
Featured/ 06/24/2026 · 11:47 AM

Raymond James Highlights Viking’s New Amylin-Based Weight Loss Drug VK3019 Entering Clinic

Viking Therapeutics advances its obesity portfolio with the start of a Phase 1 trial for VK3019, a novel dual amylin and calcitonin receptor agonist. Analyst sees major potential.

/ Subscriber only
Cantor Fitzgerald Initiates Overweight Coverage on Silence Therapeutics (SLN), Calls Stock “Materially Undervalued”
Featured/ 06/24/2026 · 10:39 AM

Cantor Fitzgerald Initiates Overweight Coverage on Silence Therapeutics, Calls Stock “Materially Undervalued”

The firm initiated Overweight coverage citing strong divesiran Phase 2 potential and 160%+ upside.

/ Subscriber only
CEO Moshe Mizrahy’s Group Offers to Take InMode Private at $16.20 Per Share
06/24/2026 · 10:14 AM

CEO Moshe Mizrahy’s Group Offers to Take InMode Private at $16.20 Per Share

Board forms special committee to evaluate the offer.

/ Subscriber only
  • UP↑
  • Terms/Privacy
  • Sign up
  • Sign in
  • Discord
  • X
  • Bluesky
  • Telegram
  • Reach out →
  • Invest ↗
  • NOTRELOAD AI
DON'T FALL BEHIND. ©2026
Email address Subscribe